Biotechnology Innovation Organization
The Biotechnology Innovation Organization is a prominent association representing over 1,000 biotechnology companies, academic institutions, and related organizations. Founded in 1993 and based in Washington, D.C., it was established through the merger of the Industrial Biotechnology Association and the Association of Biotechnology Companies. The organization focuses on providing valuable information, advocacy, and business development services to its members. Its efforts encompass the research and development of a wide range of biotechnology products, including pharmaceuticals, drug discovery, genomics, and proteomics, as well as solutions in agriculture, industry, and environmental sustainability. By promoting collaboration and innovation within the biotechnology sector, the organization aims to address critical challenges such as healthcare, climate change, and food security.
Non Equity Assistance in 2020
Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.